Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | NKTR-255 in multiple myeloma and NHL

Nina Shah • 10 Dec 2021
ASH 2021
Lymphoma Multiple Myeloma Non-Hodgkin Lymphoma Antibodies NKTR-255 Rituximab
KarMMa

Nina Shah, MD, University of California, San Francisco, CA, presents preliminary findings from the Phase I trial (NCT04136756) of NKTR-255, a recombinant human interleukin (IL)-15 agonist, in patients with relapsed/refractory hematologic malignancies. NKTR-255 targets IL-15Rα receptors and were found to expand T-cells and natural killer (NK) cells in preclinical models. Patients generally tolerated the therapy, and NKTR-255 managed to increase IL-6 levels. Dr Shah additionally discusses potential its uses in non-Hodgkin lymphoma (NHL), or with rituximab in multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Nina Shah

19:39
T-Cell Engagers: targets, challenges and opportunity
Hermann Einsele et al. • 27 Mar 2022
2:15
Reporting patient experiences during the KarMMa trial
Nina Shah • 10 Dec 2021
2:06
Subanalysis of the KarMMa Trial: Predicting complete response to CAR-T in multiple myeloma
Nina Shah • 10 Dec 2021
1:12
The role of immunotherapy in multiple myeloma
Nina Shah • 10 Dec 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals